CRISPR Therapeutics AG — Director's Dealing 2022

Aug 18, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2022-08-16

Reporting Person: Smith Brendan (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-08-16	Restricted Stock Units	$	A	10000	Acquired		Common Shares (10000)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F2: The restricted stock units shall vest in full on February 16, 2025, subject to continued service to the Company or any of its subsidiaries.